JCT  Vol.4 No.9 , November 2013
Combined Treatment Strategy and Outcome of High Risk Neuroblastoma: Experience of the Children’s Cancer Hospital-Egypt
Abstract: Background: Neuroblastoma (NB) is remarkable for its wide spectrum of clinical behavior and biological characteristics in relation to outcome. The use of aggressive therapy, including autologous hematopoietic stem cell transplantation (HSCT) and the addition of isoretionin (cis-Retinoic Acid/cis-RA), has increased survival rates of patients with advanced disease. Methods: Pediatric 271 newly diagnosed high risk NB patients were prospectively enrolled into the study. Patients received neoadjuvant chemotherapy of alternating cycles: [cyclophosphamide, doxorubicin, vincristine (CAdO)] and [etoposide, carboplatin]. Intensification courses of “ICE” (ifosfamide, carboplatin, and etoposide) regimen were administered to patients with bone marrow (BM) residual infiltration. Whenever safely feasible, complete surgical resection or debulking of the primary tumor was attempted for patients achieving partial response. Eligible patients underwent HSCT, while radiation therapy to the primary and metastatic sites, as well as maintenance with cis-RA was given for 6 months. Results: The median age of our patients was 2.8 years with male to female ratio of 1.65:1. At 4 years, the overall and event free survivals were 33.7% and 23.3% for the entire group under study, with significantly higher rates (42.7% and 35.6%, respectively) for HSCT patients (n = 94; p < 0.001). The outcome was also significantly correlated with response to induction therapy, pathological subtype, as well as other variables. Conclusion: Myeloablative therapy followed by stem cell rescue is regarded as the most important goal of high risk NB treatment to improve survival till present. Each of consolidation HSCT, post induction disease status, as well as international neuroblastoma pathology classification (INPC) subtype was an independent predictive variable of survival. A collaborative effort with an emphasis on biologic characteristics of aggressive disease and tailored therapy needs to be strengthened to further our understanding of this disease.
Cite this paper: E. Moussa, M. Fawzy, A. Younis, M. Shafei, M. Zaghloul, N. Kinaai, A. Refaat, N. Atta and A. Haddad, "Combined Treatment Strategy and Outcome of High Risk Neuroblastoma: Experience of the Children’s Cancer Hospital-Egypt," Journal of Cancer Therapy, Vol. 4 No. 9, 2013, pp. 1435-1442. doi: 10.4236/jct.2013.49171.

[1]   S. L. Cohn, “Surveillance, Epidemiology, and End Results (SEER) Database,” 2007, National Cancer Institute.

[2]   S. L. Cohn, A. D. J. Pearson, W. B. London, T. Monclair, P. F. Ambros, G. M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel and K. K. Matthay, “The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task force Report,” Journal of Clinical Oncology, Vol. 27, No. 2, 2009, pp. 289-297. JCO.2008.16.6785

[3]   M. Kubota, M. Yagi, S. Kanada, N. Okuyama, Y. Kinoshita, S. Yamazaki, K. Asami, A. Ogawa and T. Watanabe, “Long-Term Follow-Up Status of Patients With Neuroblastoma after Undergoing Either Aggressive Surgery or Chemotherapy—A Single Institutional Study,” Journal of Pediatric Surgery, Vol. 39, No. 9, 2004, pp. 1328-1332.

[4]   M. Kaneko, Y. Tsuchida, H. Muqishima, N. Ohnuma, K. Yamamoto, K. Kawa, M. Iwafuchi, T. Sawada and S. Suita, “Intensified Chemotherapy Increases the Survival Rates in Patients with Stage 4 Neuroblastoma with MYCN Amplification,” Journal of Pediatric Hematology/Oncology, Vol. 24, No. 8, 2002, pp. 613-621.

[5]   K. K. Matthay, C. P. Reynolds, R. C. Seeger, H. Shimada, E. S. Adkins, D. Haas-Kogan, R. B. Gerbing, W. B. London and J. G. Villablanca, “Long-Term Results for Children with High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children’s Oncology Group Study,” Journal of Clinical Oncology, Vol. 27, No. 7, 2009, pp. 1007-1013.

[6]   B. Kushner, K. Kramer, S. Modak and N. K. Cheung, “Anti-GD2 Monoclonal Antibody 3F8 Plus Granulocyte Macrophage Colony Stimulating Factor for Primary Refractory Neuroblastoma in Bone Marrow,” Proceedings of ASCO, Vol. 25, 2007, p. 9502.

[7]   K. W. Sung, M. H. Son, S. H. Lee, K. H. Yoo, H. H. Koo, J. Y. Kim, E. J. Cho, S. K. Lee, Y. S. Choi, D. H. Lim, J. S. Kim and D. W. Kim, “Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma: Results of SMC NB-2004 Study,” Bone Marrow Transplant, Vol. 48, No. 1, 2013, pp. 68-73.

[8]   G. Surico, P. Muggeo, F. De Leonardis and N. Rigillo, “New Paclitaxel Cisplatin Based Chemotherapy Regimen for Advanced Stage, Recurrent, or Refractory Neuroblastoma—Preliminary Report,” Medical and Pediatric Oncology, Vol. 40, No. 2, 2003, pp. 130-132.

[9]   G. M. Brodeur, J. Pritchard, F. Berthold, N. L. Carlsen, V. Castel, R. P. Castelberry, B. De Bernardi, A. E. Evans, M. Favrot, F. Hedborg, et al., “Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment,” Journal of Clinical Oncology, Vol. 11, 1993, pp. 1466-1477.

[10]   O. Burques, S. Navarro, R. Noquera, A. Pellín, A. Ruiz, V. Castel and A. Llombart-Bosch, “Prognostic Value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian Stroma-Poor) and Comparison with Other Prognostic Factors: A Study of 182 Cases from the Spanish Neuroblastoma Registry,” Virchows Archives, Vol. 449, No. 4, 2006, pp. 410-420.

[11]   Y. Hachitanda, M. Saito, I. Mori and M. Hamazaki, “Application of Fluorescent in Situ Hybridization to Detect N-myc Gene Amplification on Paraffin-Embedded Tissue Sections of Neuroblastoma,” Medical and Pediatric Oncology, Vol. 29, 1997, pp. 135-138.

[12]   G. M. Brodeur, M. D. Hogarty, Y. P. Mosse and J. M. Maris, “Neuroblastoma,” In: P. A. Pizzo, P. C. Adamson and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology. 6th Edition, Lippincott Williams and Wilkins, Philadelphia, 2011, pp. 886-922.

[13]   B. H. Kushner, R. J. O’Reilly, M. LaQuaglia and N. K. Cheung, “Dose-Intensive Use of Cyclophosphamide in Ablation of Neuroblastoma,” Cancer, Vol. 66, 1990, pp. 1095-1100.<1095::AID-CNCR2820660603>3.0.CO;2-0

[14]   G. J. Veal, M. Cole, J. Errington, A. D. Pearson, A. B. Foot, G. Whyman and A. V. Boddy, “UKCCSG Pharmacology Working Group. Pharmacokinetics and Metabolism of 13-Cis-Retinoic Acid (Isotretinoin) in Children with High-Risk Neuroblastoma—A Study of the United Kingdom Children’s Cancer Study Group,” British Journal of Cancer, Vol. 96, No. 3, 2007, pp. 424-431. sj.bjc.6603554

[15]   J. M. Maris, M. D. Hogarty, R. Baqatell and S. L. Cohn, “Neuroblastoma,” Lancet, Vol. 369, No. 9579, 2007, pp. 2106-2120.

[16]   K. K. Matthay, J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris, N. K. Ramsay, P. Swift, H. Shimada, C. T. Black, G. M. Brodeur, R. B. Gerbing and C. P. Reynolds, “Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. Children’s Cancer Group,” The New England Journal of Medicine, Vol. 341, 1999, pp. 1165-1173.

[17]   M. Kaneko, Y. Tsuchida, J. Uchino, T. Takeda, M. Iwafuchi, N. Ohnuma, H. Mugishima, J. Yokoyama, H. Nishihira, K. Nakada, S. Sasaki, T. Sawada, K. Kawa, N. Nagahara, S. Suita and S. Sawaguchi, “Treatment Results of Advanced Neuroblastoma with the First Japanese Study Group Protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma,” Journal of Pediatric Hematology/Oncology, Vol. 21, No. 3, 1999, pp. 190-197.

[18]   C Tan, S. M. Sabai, A. S. Tin, T. C. Quah and L. Aung, “Neuroblastoma: Experience from National University Health System, Singapore (1987-2008),” Singapore Medical Journal, Vol. 53, 2012, pp. 19-25.

[19]   A. L. Yu, A. L. Gilman, M. F. Ozkaynak, W. B. London, S. G. Kreissman, H. X Chen, M. Smith, B. Anderson, J. G. Villablanca, K. K. Matthay, H. Shimada, S. A. Grupp, R. Seeger, C. P. Reynolds, A. Buxton, R. A. Reisfeld, S. D. Gillies, S. L. Cohn, J. M. Maris and P. M. Sondel, “Children’s Oncology Group. Anti-GD2 Antibody with GMCSF, Interleukin-2, and Isotretinoin for Neuroblastoma,” The New England Journal of Medicine, Vol. 363, No. 14, 2010, pp. 1324-1334. NEJMoa0911123

[20]   R. C. Seeger, C. P. Reynolds, R. Gallego, D. O. Stram, R. B. Gerbing and K. K. Matthay, “Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children’s Cancer Group Study,” Journal of Clinical Oncology, Vol. 18, 2000, pp. 4067-4076.

[21]   E. M. Kiely, “Radical Surgery for Abdominal Neuroblastoma,” Seminars in Surgical Oncology, Vol. 9, No. 6, 1993, pp. 489-492.

[22]   D. von Schweinitz, B. Hero and F. Berthold, “The Impact of Surgical Radicality on Outcome in Childhood Neuroblastoma,” European Journal of Pediatric Surgery, Vol. 12, No. 6, 2002, pp. 402-409.

[23]   M. P. La Quaglia, B. H. Kushner, W. Su, G. Heller, K. Kramer, S. Abramson, N. Rosen, S. Wolden and N. K. Cheung, “The Impact of Gross Total Resection on Local Control and Survival in High-Risk Neuroblastoma,” Journal of Pediatric Surgery, Vol. 39, No. 3, 2004, pp. 412-417. 10.1016/j.jpedsurg.2003.11.028

[24]   A. L. Koivusalo, M. P. Pakarinen, R. J. Rintala and U. M. Saarinen-Pihkala, “Surgical Treatment of Neuroblastoma: Twenty-Three Years of Experience at a Single Institution,” Surgery Today, 2013, Epub Ahead of Print.

[25]   A. M. Davidoff, “Neuroblastoma,” Seminars in Pediatric Surgery, Vol. 21, No. 1, 2012, pp. 2-14.

[26]   S. Mueller and K. K. Matthay, “Neuroblastoma: Biology and Staging,” Current Oncology Reports, Vol. 11, No. 6, 2009, pp. 431-438.